Jacob Gottlieb, a very successful investor in the healthcare sector, recently added Altium Captital, a new segment, into his portfolio. Altium capital is a fund based out of New York City with top holdings Represented by Oramed Pharmaceuticals, Amarin Corporation, and Oragenics. Oramed represents Altium’s First investment in the medical industry and has shown immense promise with its development of oral diabetes medications. It currently holds a patent on an alternative ingestible insulin capsule and other diabetes treatments. Ameren Corporation, based out of Dublin, represents a high-growth investment prospect due primarily to its research and development of medications meant to improve cardiovascular health. One such FDA-approved drug from Ameren is called Vascepa which utilizes the company’s unique lipid science knowledge. Oragenics focuses on replacement therapy in which novel antibiotics are used as an effective counter against infectious diseases as well as oral mucositis. The company’s synergistic relationship with Intrexon Corporation allows for rapid development of novel antibiotics used to target potent bacterial strains.
Notably, Gottlieb now occupies the same office space as his longtime colleague Stuart Weisbrod. their previous work together at Merlin biomed group Is indicative of potential cooperative business ventures in the future. Gottlieb’s history indicates a rich experience within the medical field both financial and professional. He has both an undergraduate degree in economics as well as a medical doctorate. His prior experience includes work at Balyasny Asset Management and his previously mentioned tenure at Merlin biomed group where he was a very successful investment portfolio manager. These experiences have enabled Gottlieb to found his own 8 billion dollar hedge fund Visium Asset Management in 2005, although it was not without controversy. The company was hit with an insider trading scandal in 2016, though despite the setback, Gottlieb was cleared of any legal wrongdoing.